Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267820 | 0.79 | HTR6 (0.40) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL17489068 | 0.79 | HTR6 (0.40) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL1936077 | 0.78 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6976334 | 0.78 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL6970103 | 0.78 | LMNA (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL25821347 | 0.77 | KDM4E (0.35) | — | |
| Hydrochloric Acid SCHEMBL1936476 | 0.77 | HPGD (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3279117 | 0.77 | HPGD (0.43) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL18922319 | 0.76 | HTR6 (0.38) | HTR6HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL3995290 | 0.75 | HTR6 (0.47) | HTR6HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | HTR6 2280/4885HPGD 4430/4885KMT2A 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.